Announcements Trials
Browse Landscape

Phase

Phase 3 2Phase 1/2 1Phase 1 1

Status

Completed 2

Sponsor Class

INDUSTRY 2

Study Type

Interventional 2

Sponsor

Cancer Type

Gastrointestinal 2

Conditions

Pancreatic Neoplasms 10Carcinoma, Non-Small-Cell Lung 9Triple Negative Breast Neoplasms 8Breast Neoplasms 8Parkinson Disease 4, Autosomal Dominant Lewy Body 7Neoplasms 5Neoplasm Metastasis 4Lung Neoplasms 4Adenocarcinoma 3Stomach Neoplasms 2Pancreatic Diseases 2Neoplasms by Site 2Endocrine System Diseases 2Endocrine Gland Neoplasms 2Digestive System Neoplasms 2Digestive System Diseases 2Carcinoma, Pancreatic Ductal 2Carcinoma, Ductal, Breast 2Carcinoma 2Uterine Cervical Neoplasms 1Squamous Cell Non-small Cell Lung Cancer 1Squamous Cell Carcinoma of Head and Neck 1Radiation Injuries 1Pericardial Effusion 1Pancreatic Cancer Non-resectable 1Pancreatic Adenocarcinoma 1Non-Small-Cell Lung 1Non Small Cell Lung Cancer NSCLC 1Neuralgia 1Neoplasms, Unknown Primary 1

Interventions

Gemcitabine 3Albumin-Bound Paclitaxel 2130-nm albumin-bound paclitaxel 2napabucasin 1ganitumab 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Phase 3 × Endocrine Gland Neoplasms × Albumin-Bound Paclitaxel × Clear all
NCT02993731 2023-11-15

CanStem111P

Sumitomo Pharma America, Inc.

Phase 3 Completed
1,134 enrolled 18 charts
Gastrointestinal

Adenocarcinoma, Digestive System Diseases, Digestive System Neoplasms, Endocrine System Diseases, Endocrine Gland Neoplasms, Neoplasms, Neoplasms by Histologic Type, Neoplasms by Site, Neoplasms, Glandular and Epithelial, Pancreatic Diseases, Pancreatic Neoplasms, Carcinoma, Pancreatic Ductal

NCT01964430 2023-06-28

apact

Celgene

Phase 3 Completed
866 enrolled 21 charts
Gastrointestinal

Adenocarcinoma, Digestive System Diseases, Digestive System Neoplasms, Endocrine System Diseases, Endocrine Gland Neoplasms, Neoplasms, Neoplasms by Site, Pancreatic Diseases, Pancreatic Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡